Callisto Pharmaceuticals’ Interim Phase II Data Of Atiprimod In Advanced Carcinoid Cancer To Be Presented At ASCO Conference

Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced that interim data from the company’s ongoing open-label Phase II clinical trial of Atiprimod in advanced carcinoid cancer, will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago May 30-June 3, 2008.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 17th, 2008